Interleukin 6 (IL-6) is a major growth factor for myeloma cells and retinoids have been shown to inhibit expression of the interleukin 6 receptor (IL-6R). We performed a pilot study to assess the efficacy and tolerability of 13cis retinoic acid (13cRA) and dexamethasone (Dex), when added to interferon a (IFNa) as maintenance therapy post autologous stem cell transplantation. Between 90 and 120 days post stem cell transplantation, 33 patients were started on 13cRA 1 mg/kg p.o. daily for 14 days and Dex 40 mg p.o daily for 5 days every month. 13cRA was dose escalated by 0.5 mg/kg/month to 2 mg/kg. Seventeen patients had a persistent paraprotein post transplant. Overall, a response to therapy was observed in 11/17 (64%), with a complete response in 4/17 (23.5%) and a partial response (X50% paraprotein decline) in 7/17 (41%). With a median follow-up of 34.8 months, 22/33 (66%) demonstrated disease progression and 11/33 (33%) died. The median progression-free survival from diagnosis was 34.7 months. Although a decline in paraprotein was frequently observed on triple therapy, many patients discontinued therapy due to the side-effects of the IFNa. Future trials should be designed using 13cRA and Dex alone. Bone Marrow Transplantation (2005) 35, 979-984.
retinoic acid; dexamethasone High-dose chemotherapy (HDCT) with autologous stem cell transplant (ASCT) results in a higher rate of complete response (CR) and longer progression-free and overall survival (OS) when compared to standard dose chemotherapy for patients with multiple myeloma. 1, 2 However, trials with high-dose therapy in multiple myeloma do not show a plateau in the survival curves and a majority of the patients relapse and die. While interferon-alpha (IFNa) post transplant has been shown in randomized trials to prolong remission time, it has not shown to improve OS. 3 Therefore, there is great interest in developing therapeutic strategies that can further improve outcomes.
Interleukin 6 (IL-6) is a major growth factor for myeloma cells. Targeting the IL-6 receptor (IL-6R) is theoretically an attractive strategy to arrest myeloma cell growth. [4] [5] [6] In vitro, retinoids have been shown to inhibit IL6Ra-chain expression and decrease myeloma cell proliferation. 7, 8 The few clinical trials studying retinoids for the treatment of multiple myeloma, have all used all-trans retinoic acid (ATRA) as the retinoid of choice and have been limited to patients with refractory disease. 9, 10 In this setting, ATRA has failed to show clinical efficacy. However, 13cis retinoic acid (13cRA) has been shown in vitro to be the more active of the two retinoids. 11 Also, 13cRA and dexamethasone (Dex) are synergistic in inhibition of myeloma cell growth. 11, 12 In addition, biological response modifiers are known to work best when the burden of disease is minimal. HDCT is known to be very successful at reducing the malignant clone in multiple myeloma. We therefore performed a pilot study to assess the efficacy and feasibility of the combination of 13cRA and Dex, when added to IFNa (triple therapy) as maintenance therapy post HDCT and ASCT.
Patients and methods

Study population
Patients diagnosed with multiple myeloma were enrolled in this prospective trial prior to treatment with HDCT and ASCT at the Washington University School of Medicine. The trial was approved by the Institutional Review Board of Washington University. Patients gave informed consent according to institutional standards on enrollment prior to transplantation. Patients received induction therapy at the discretion of the referring oncologist. Patients were eligible for HDCT if they had responsive disease. Following completion of induction therapy, stem cells were mobilized with G-CSF 10 mg/kg and patients underwent apheresis for collection of peripheral blood stem cells (goal 2.5 Â 10 6 CD34 þ ve stem cells/kg body wt). All patients received high-dose melphalan (200 mg/m 2 ) as a conditioning regimen.
Final eligibility was confirmed between days 90 and 120 post transplant (after maximum paraprotein response to HDCT had been attained). To be eligible at this point patients were required to have: (1) a paraprotein (IgG or IgA) level of less than 5 g/dl, (2) adequate hematological recovery post transplant, including a platelet count 4100 000/mm 3 and an absolute neutrophile count (ANC) 42000/mm 3 , and (3) a negative pregnancy test for females of child-bearing potential. Patients were excluded if they had severe hepatic disease (AST, ALT alkaline phosphatase, or total bilirubin greater than two times normal), compromised renal function (serum creatinine 42.5 mg/dl) or biopsy-proven amyloidosis.
Therapy
Between 90 and 120 days post ASCT, patients were started on 13cRA 1 mg/kg p.o. daily for 14 days and Dex 40 mg p.o daily for 5 days every month. 13cRA was dose escalated by 0.5 mg/kg/month to 2 mg/kg. Therapy was continued until disease progression or failure to tolerate the drug regimen. In addition, patients received IFNa (Roferon A) 3 MU s.q. t.i.w., and bisphosphonates monthly.
Criteria for dose reduction and or discontinuation were specified in the protocol. The interferon alpha dose was reduced to 2 MU if the platelet count fell below 50 000/mm 3 or if the ANC fell below 1500/mm 3 . For the first episode of a platelet count less than 25 000/mm 3 and/or ANC less than 1000/mm 3 , further doses of IFNa were held until recovery of the platelet count to greater than 50 000/mm 3 , and ANC greater than 1500/mm 3 . The interferon alpha was then reintroduced at a dose of 2 MU. For a second episode of a platelet count below 25 000/m 3 and an ANC less than 1000/ mm 3 , interferon was held again, and then reintroduced following recovery. However, after a third episode, the patient was removed from the study.
The dose of retinoic acid was reduced by 0.5 mg/kg/cycle with subsequent cycles (until a tolerable dose was reached) in the event of (1) painful chelitis, (2) severe conjunctivitis, (3) painful erythema, vesiculation, and pruritis, (4) headaches not controlled with vicodin or equipotent analgesic, (5) triglycerides greater than 500, or (6) bilirubin, AST, ALT, or alkaline phosphatase greater than two times normal.
The study drug combination was discontinued if: (1) the platelet count was less than 25 000/mm 3 and/or ANC less than 1000/mm 3 on three separate occasions at an interferon dose of 2 MU, (2) if the retinoic acid reduction to 0.5 mg/kg did not resolve the side-effects (as above) within 3 months, (3) any grade 3 or 4 allergic reaction, (4) serious adverse event related to drug administration, (5) any adverse event that the investigator felt precluded further treatment, and (6) if there was evidence of disease progression by any of the criteria listed in the following paragraph.
Data collection
Disease-related symptoms and treatment-related toxicities were evaluated every 3 months from the time of entry into the study until the patient was discontinued from the study, by administering a thorough review of systems by the physicians at the Washington University Bone Marrow Transplant Clinic. Patients were required to be followed every month. A complete blood count, serum protein electrophoresis (SPEP), urine (UPEP and 24 h urine for protein), beta 2 microglobulin, triglycerides/cholesterol profile, and hepatic function profile were obtained prior to transplant, prior to start of triple drug therapy, and every 3 months thereafter. A skeletal series and bone marrow biopsy were obtained prior to transplant, prior to start of triple drug therapy, and every 6 months thereafter. Karyotype analysis included conventional cytogenetic analysis and fluorescence in situ hybridization (FISH) analysis for the probe specific for the RB gene locus on 13q14. Serum levels of IL-6 and IL-6R were measured in a subset of patients at baseline prior to treatment with triple therapy and on day 15 after initiation of the first cycle of triple therapy treatment.
Definitions
All responses were defined based on the criteria developed by Blade et al 13 in conjunction with the myeloma research. Briefly, a CR was defined by the disappearance of all paraprotein by biochemical tests, follow-up bone marrow with less than 5% plasma cells on aspiration or core biopsy, and skeletal films showing either re-calcification or no change (NC) in the size or number of osteolytic lesions. Any soft tissue lesions should have completely disappeared. In terms of serum mononclonal protein levels, a partial response (PR) was defined as a decline in paraprotein by X50% documented on two SPEP measurements 3 months apart. A minimal response (MR) required 25-49% reduction in the level of the serum monoclonal protein, while NC was declared if there was neither a MR nor evidence of progressive disease.
Progressive disease was defined by a 425% increase in the paraprotein level documented on two SPEP measurements 3 months apart. Relapse required any one of the following: (1) the reappearance of the paraprotein that had disappeared post transplant on two serial SPEP measurements 3 months apart, (2) an increase by 100% in crosssectional dimension of any specific lytic lesion (41 cm), (3) increase in the number of lytic lesions from previous radiographs, or (4) the development of extramedullary sites of disease.
End points and statistics
The primary end point of the study was a 50% or more reduction in the paraprotein after 3 or more months on triple therapy. Secondary end points were time to disease progression (TTP), OS, toxicity, and tolerability of the triple drug therapy. Time to progression was determined both from time of diagnosis and from time of initiation of triple drug therapy. Based on historical data from our institution (unpublished data), only 10% of patients who had a detectable paraprotein level 3 months post transplant showed a further X50% decline in paraprotein level when checked thereafter. We considered it would be clinically significant if, with the study drug combination, 25% patients achieved a X50% reduction in their paraprotein level within the next 90 days. Based on a Simons two-stage design, with a p 0 ¼ 0.10 and a p 1 ¼ 0.25, a total of 21 patients were needed to be enrolled on the study in the first stage. If three or more responses were observed in these initial 21 patients, an additional 29 patients were planned for enrollment. If eight or more of the 50 patients enrolled on the trial showed a paraprotein response by day 180, the null hypothesis would be rejected. The study was designed with an alpha error of 0.1 and a power of 0.9. Anticipating a dropout rate of 10%, we aimed to enroll a total of 55 patients for purposes of assessing a response. We expected to accrue 25 patients a year into the study. As several patients in the initial cohort did not have a measurable paraprotein at days 90-120, the accrual was increased to allow enough patients for assessment of the primary end point.
Results
Baseline characteristics
A total of 62 patients between 7/99 and 9/02 provided informed consent for enrollment on the protocol prior to HDCT and ASCT. In all, 33 patients began triple therapy. Table 1 shows the demographic and clinical characteristics of these patients. Altogether, 29 patients did not start triple drug therapy (15 patients withdrew consent, eight patients had insufficient blood count recovery to start therapy, two developed disease progression prior to therapy, one patient was deemed ineligible due to severe cardiac problems, and three patients expired).
Response rates
With a median follow-up of 34.8 months (7.2-55 months), patients have received a median of 10 cycles (1-57) of triple therapy. Four patients currently remain on therapy. In all, 15 patients were maintained on triple therapy for X1 year and five patients were on therapy for X2 years.
Of 33 patients who began triple drug therapy, 27 completed at least 3 months of triple therapy. Of these 27 patients, 17 had a detectable paraprotein at the time of initiating triple therapy and were assessable for the primary end point. Overall a response was observed in 11/17 (64%), with a CR in 4/17 (23.5%) and a PR (X50% paraprotein decline) in 7/17 (41%). Response rates by stage of disease are shown in Table 2 . On an intention to treat analysis, of the 33 patients who began triple drug therapy, 4/33 (12%) had CR and 7/33 (21%) had a PR. There were four patients who had no decline in the paraprotein level between measurements immediately prior to HDCT and measurements prior to starting triple drug therapy. Three of these four patients had a X50% decline in paraprotein levels.
Survival
On the last review, 22/33 (67%) demonstrated disease progression and 11/33 (33%) had died. The median TTP from diagnosis was 31 months (11-63 months). The median time to progression from after initiating triple drug therapy was 16 months (1.2-52 months). Of the 27 patients who completed at least 3 months of therapy, 16 (59%) demonstrated disease progression. Within this subgroup of 27 patients, the median TTP from diagnosis was 30.1 months (16-63 months) and the median time to progression from initiating triple drug therapy was 16 months (10-52 months). Time to progression by stage of disease for the patients with a measurable paraprotein at start of triple drug therapy is shown in Table 2 . A Kaplan-Meier (KM) analysis on an intention to treat basis shows a median progression-free survival (PFS) of 34.7 months (95% CI 29.2, 53.7) from diagnosis ( Figure 1) . By KM analysis, a median OS has not been reached (Figure 2 ). 
Toxicity
The majority of toxicities were grade I or II in severity (Table 3) . However, a number of patients required dose reductions of both 13cRA and IFNa due to side-effects (Table 4) . Also, of the 33 patients initiating triple therapy, 15 (45%) had to discontinue therapy due to side-effects (five neurologic, three dermatologic, one hematologic, four malaise/weakness, one hypertriglyceridemia, one progressive liver disease).
IL-6/IL-6R levels
Serum samples for 16 patients were available for IL-6 and IL-6R levels pre and post drug initiation. Figure 3 shows the percent change in IL-6 and IL-6R levels after initiation of the triple therapy. No correlation could be made between the change in IL-6/IL-6R levels and response to triple drug therapy.
Discussion
This is the first trial to report on outcomes of 13cRA and dexamethasone when added to IFNa as post-transplant maintenance therapy for patients with MM. Unfortunately, due to the single-arm Phase II trial design, it is not possible to analyze the effects of each of these three individual drugs to the efficacy of the therapeutic regimen. However, an attempt can be made to compare our results with that of other published series of patients treated with IFNa and dexamethasone alone or in combination.
In a randomized study of IFNa-2b vs placebo as maintenance treatment, it was noted that the paraprotein levels actually did not decrease in patients given IFNa. 14 Another small study reporting the kinetics of paraprotein clearance after autografting for multiple myeloma also 13cRA þ Dex þ alpha IFN maintenance therapy following HDCT J Friedman et al found that IFNa did not influence the number of patients clearing paraprotein. 15 Data on the influence of Dex on the clearance of paraprotein post transplant are scarce in the literature. However, Dex when given to untreated myeloma patients in a dose totaling 480 mg per month had a response rate of 45%. 16 We would predict a lower response rate with Dex in our patients, a cohort that is no longer chemotherapy naı¨ve. Additionally, in our study we gave only 200 mg of Dex per month. Data from our trial show an overall response rate of 64% in the subgroup of patients treated with 3 months of triple therapy. As IFNa does not appear to affect paraprotein levels and response rates to more than double the dose of dexamethasone are lower, this suggests that the addition of 13cRA may have contributed to the improved response rate observed in this trial.
Again, to assess the impact of the triple drug therapy on survival, we have to turn to other published series. There are extensive data on remission duration and survival with IFNa for maintenance therapy in MM. Most studies of HDCT for MM report PFS from time of diagnosis of MM. Following conventional chemotherapy, randomized studies indicate that IFNa prolongs remission duration by 5-12 months. 14, [17] [18] [19] These trials also found a minimal or no survival advantage in the IFNa-treated patients. Plateau phase duration in those patients treated with IFNa ranged from 14 to 16 months. In the Intergroupe Francais Du Myelome (IFM) study comparing autologous transplantation with conventional chemotherapy, patients in both arms received IFNa as maintenance therapy. 1 The probability of event-free survival in the patients receiving the autologous transplant was 27 months from diagnosis. A more recent trial comparing single vs double transplant for MM, also using IFNa as maintenance therapy, found a probability of event-free survival of 25 months in the single transplant arm. 20 There is a paucity of data on the use of steroids as maintenance therapy after HDCT for MM. However, steroids alone have demonstrated improved PFS in the setting of maintenance therapy following conventional therapy for MM. The Southwest Oncology Group (SWOG) randomized 126 patients to either 10 mg (physiologic doses) or 50 mg of prednisone every other day after response to VAD therapy. 21 In the high-dose prednisone arm, PFS was 14 months, a 9-month improvement over the low-dose prednisone arm. Also, steroids have been shown to enhance the activity of IFNa. In a SWOG study, 89 patients who achieved remission with VAD were randomized to IFNa or IFNa and prednisone. 22 Patients who received IFNa and prednisone had a median PFS of 19 months, a 10-month improvement over the IFNa alone arm. In our trial, we report a median PFS of 34.7 months from the time of diagnosis. Again, it is tempting to speculate that 13cis RA may have been responsible for the longer PFS observed in our study. Owing to the short follow-up, we cannot comment on OS. Also, given the increasing availability of new drugs and salvage regimens, a comparison of OS to historical controls may not be possible.
There was a substantial amount of toxicity observed with the three-drug combination. The most common side-effects causing dose reductions of the 13cRA were dermatological (chelitis, erythema, dry skin), observed in 22 (66%) patients. Only 5/33 (15%) patients required two or more reductions in the 13cRA dose. These side-effects are similar to those reported in other trials using 13cis RA. 23, 24 However, interferon contributed significantly to the morbidity of the triple drug regimen. In fact, 16/33 (48%) patients required either one or two dose reductions in the IFNa during their course of therapy. Side-effects attributable to IFNa included headache, depression, and fatigue. This is similar to the side-effect profile of IFNa observed in other trials. 14, 17, 19, 20 Major side-effects in our study included grade I/II CNS toxicity in 54% of the patients, and 48% with grade I/II generalized malaise/fatigue. In the Nordic Myeloma Study Group (1996) , patients reported a similar CNS grade I/II toxicity of 50, and 50% with myalgias/fatigue.
14 A significant number 15/33 (45%) of our patients who began therapy eventually discontinued triple therapy due to side-effects. This is similar to the experience in the Nordic Myeloma Study Group (1996) using interferon alone as maintenance therapy, in which 40% of the patients had stopped using interferon all together by 18 months.
14 Therefore, it is likely that omission of IFNa from the triple therapy regimen would have allowed more patients to stay on 13cis RA and Dex longer.
By collection of serum IL-6 and IL-6R levels, an attempt was made to correlate any response to triple therapy with these biological markers. Unfortunately, we were unable to establish a link between changes in IL-6 and IL-6R levels and decline in paraprotein levels on triple drug therapy. Perhaps, a larger sample size or sampling at alternative time points may have been able to establish a correlation.
Though limited by small patient numbers and a phase II trial design, this is the first trial to examine the use of 13cRA in combination with Dex and IFNa in the maintenance setting after HDCT for MM. We report an overall paraprotein response rate of 64% to this therapy and a PFS of 34.7 months from time of diagnosis. The toxicity associated with interferon prevented many patients from staying on therapy, and therefore reduced the time and numbers of patients who were exposed to 13cRA and Dex. When we started this trial, IFNa was the accepted standard of care at most transplant centers. However, the utility of interferon for post-transplant maintenance therapy is increasingly being debated. Recently, a SWOG trial showed that interferon maintenance did not improve survival post transplant. 25 Therefore, it appears that IFNa may safely be excluded from post-transplant maintenance therapy. As interferon has not been shown to prolong OS, a trial using 13cRA with Dex alone is warranted.
